TY - JOUR
T1 - Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
AU - Chi, Susan N.
AU - Zimmerman, Mary Ann
AU - Yao, Xiaopan
AU - Cohen, Kenneth J.
AU - Burger, Peter
AU - Biegel, Jaclyn A.
AU - Rorke-Adams, Lucy B.
AU - Fisher, Michael J.
AU - Janss, Anna
AU - Mazewski, Claire
AU - Goldman, Stewart
AU - Manley, Peter E.
AU - Bowers, Daniel C.
AU - Bendel, Anne
AU - Rubin, Joshua
AU - Turner, Christopher D.
AU - Marcus, Karen J.
AU - Goumnerova, Liliana
AU - Ullrich, Nicole J.
AU - Kieran, Mark W.
PY - 2009/1/20
Y1 - 2009/1/20
N2 - Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. Patients and Methods Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralum-bar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. Results Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% ± 13% and 70% ± 10%, respectively. Median overall survival has not yet been reached. Conclusion This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
AB - Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. Patients and Methods Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralum-bar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. Results Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% ± 13% and 70% ± 10%, respectively. Median overall survival has not yet been reached. Conclusion This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
UR - http://www.scopus.com/inward/record.url?scp=58549119586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58549119586&partnerID=8YFLogxK
U2 - 10.1200/JCO.2008.18.7724
DO - 10.1200/JCO.2008.18.7724
M3 - Article
C2 - 19064966
AN - SCOPUS:58549119586
SN - 0732-183X
VL - 27
SP - 385
EP - 389
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -